{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:50:00Z","timestamp":1793321400413,"version":"4.5.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,24]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Type 3 von Willebrand disease with alloantibodies is a rare clinical entity with few treatment options. Emicizumab prophylaxis in such patients may result in improved hemarthrosis control, lower cost, and enhanced quality of life.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000656","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T16:49:07Z","timestamp":1568998147000},"page":"2748-2750","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-8541","authenticated-orcid":false,"given":"Angela C.","family":"Weyand","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica H.","family":"Flood","sequence":"additional","affiliation":[{"name":"Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI;"},{"name":"Children\u2019s Research Institute, Children\u2019s Hospital of Wisconsin, Milwaukee, WI;"},{"name":"Division of Hematology and Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Shavit","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-2089","authenticated-orcid":false,"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI;"},{"name":"Department of Pathology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"issue":"6","key":"2019111523325187000_B1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1055\/s-0037-1607440","article-title":"Alloantibodies in von Willebrand disease","volume":"44","author":"Franchini","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2019111523325187000_B2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/beha.2001.0139","article-title":"Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology","volume":"14","author":"Eikenboom","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2019111523325187000_B3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111523325187000_B4","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI112974","article-title":"Gene deletions correlate with the development of alloantibodies in von Willebrand disease","volume":"79","author":"Shelton-Inloes","year":"1987","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111523325187000_B5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1538-7836.2008.03146.x","article-title":"Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF?","volume":"6","author":"Federici","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111523325187000_B6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2019111523325187000_B7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s002770050323","article-title":"Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction","volume":"75","author":"Batlle","year":"1997","journal-title":"Ann Hematol"},{"issue":"8","key":"2019111523325187000_B8","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1073\/pnas.71.8.2937","article-title":"Nature of von Willebrand factor: a new assay and a specific inhibitor","volume":"71","author":"Sarji","year":"1974","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111523325187000_B9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14737159.2018.1479253","article-title":"Novel applications of array comparative genomic hybridization in molecular diagnostics","volume":"18","author":"Cheung","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"7","key":"2019111523325187000_B10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1538-7836.2012.04746.x","article-title":"Critical von Willebrand factor A1 domain residues influence type VI collagen binding","volume":"10","author":"Flood","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111523325187000_B11","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1111\/j.1365-2516.2012.02799.x","article-title":"The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor","volume":"18","author":"Pergantou","year":"2012","journal-title":"Haemophilia"},{"issue":"3","key":"2019111523325187000_B12","first-page":"348","article-title":"Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor","volume":"125","author":"Bergamaschini","year":"1995","journal-title":"J Lab Clin Med"},{"issue":"9","key":"2019111523325187000_B13","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/18\/2748\/1223241\/advancesadv2019000656.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/18\/2748\/1223241\/advancesadv2019000656.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:26:14Z","timestamp":1573863974000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/18\/2748\/374944\/Efficacy-of-emicizumab-in-a-pediatric-patient-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":13,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000656","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]}}}